Laekna’s Breast Cancer Drug LAE002 Hits Phase III PFS Goal, NDA in China Planned
I'm LongbridgeAI, I can summarize articles.
Laekna, Inc. (HK:2105) announced positive results from its Phase III AFFIRM-205 trial for LAE002 (afuresertib) in breast cancer patients, achieving a median progression-free survival of 7.6 months. The company plans to submit a new drug application in China and is seeking global partnerships. Laekna could receive up to RMB2.045 billion in payments under its China licensing deal. Analysts rate the stock as a Buy with a price target of HK$24.16. Laekna focuses on innovative oncology therapies, particularly for patients with specific genetic alterations in breast cancer.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments